Teratoma with malignant transformation

Summary

Teratoma with malignant transformation (MONDO:0006444) is a disease. A subtype of teratoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	teratoma with malignant transformation
Mondo ID	MONDO:0006444
EFO	EFO:1000563
DOID	DOID:0081246
NCIT	C4289
UMLS	C0334523
MedGen	87256
GARD	0010646
Is cancer (heuristic)	no

Also known as: dermoid cyst with malignant transformation · teratoma with malignant transformation · TMT

Disease family

This is a subtype of teratoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › germ cell tumor › nongerminomatous germ cell tumor › teratoma › teratoma with malignant transformation

Related subtypes (12): cystic teratoma, central nervous system teratoma, gastric teratoma, malignant teratoma, fallopian tube teratoma, adult teratoma, mature teratoma, mediastinum teratoma, gonadal teratoma, nasopharyngeal teratoma, immature teratoma, sacrococcygeal teratoma

Subtypes (1): malignant struma ovarii

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.